Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients
- Conditions
- Metastatic Non-small Cell Lung Cancer (NSCLC)C34Malignant neoplasm of bronchus and lung
- Registration Number
- DRKS00010126
- Lead Sponsor
- AIO-Studien-gGmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5000
1. Patients who meet all of the following criteria are eligible for the project:Histologically confirmed non-small cell lung cancer (NSCLC)
2. Informed consent no later than four weeks after start of first-line treatment
3. Age = 18 years
4. Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
5. Main project:
- Stage IV, IIIC or stage IIIB (UICC8) if patient is ineligible for curative surgery and/or radiochemotherapy
- Systemic therapy
In the main project it is strongly recommended that patients’ tumor samples are tested for EGFR mutation in exons 18-21, ALK rearrangement and ROS1 rearrangement as well as PD-L1 expression by a certified laboratory before the start of first-line treatment.
6. Satellite Stage II/III:
- Stage II, stage IIIA or stage IIIB (UICC8) if patient is eligible for curative surgery and/or radiochemotherapy
- systemic (chemo)therapy and/or radiation therapy and/or surgery
none
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method